12:00 PM EST - Afexa Life Sciences Inc : announced that Paladin Labs Inc., a leading Canadian diversified specialty pharmaceutical company, today provided an update regarding its offer for the outstanding common shares of Afexa Life Sciences Inc. Paladin believes the new terms of the enhanced Offer will be superior to the existing offer for Afexa from Valeant Pharmaceuticals International, Inc. announced on August 30, 2011. Paladin will provide the details of the enhanced offer as soon as possible following a waiver or order to cease-trade the rights plans. Afexa Life Sciences Inc
shares T.FXA are trading up $0.02 at $0.76.
